Clinical trial

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

NCT01231685

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Raltegravir Normalized identity: raltegravirView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Ritonavir-boosted protease inhibitor Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-12-01

PhasePHASE2

Conditions

HIVunresolved

Hepatitis Cunresolved

Liver Fibrosisunresolved

Interventions

RaltegravirDRUG · verified · RxNorm: raltegravir

Ritonavir-boosted protease inhibitorDRUG

Sponsors & collaborators

McGill University Health Centre/Research Institute of the McGill University Health Centrelead sponsor

Merck Sharp & Dohme LLCcollaborator

CIHR Canadian HIV Trials Networkcollaborator

Mapped research locations

TorontoOntario, Canada1 MontrealQuebec, Canada1 VancouverBritish Columbia, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01231685 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.